Symptomatic treatment for progressive multiple sclerosis

Progressive Multiple Sclerosis

Volumn 9781447123958, Issue , 2013, Pages 147-186

  Rice, Claire M ^a   Wilkins, Alastair ^b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b FRENCHAY HOSPITAL   (United Kingdom)

Author keywords

Ataxia; Fatigue; Multiple sclerosis; Neuro ophthalmology; Neuropsychiatry; Pain; Spasticity; Urogenital dysfunction

Indexed keywords

EID: 84949178011     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4471-2395-8_8     Document Type: Chapter

References (409)

1. Thompson AJ. Neurorehabilitation in multiple sclerosis: foundations, facts and fi ction. Curr Opin Neurol. 2005;18(3):267-71.
2. The UN standard rules on the equalization of opportunities for persons with disabilities. Geneva: World Health Organisation; 2001. p. 290.
3. Holper L, et al. Characterization of functioning in multiple sclerosis using the ICF. J Neurol. 2010;257(1):103-13.
4. Kesselring J, et al. Developing the ICF Core Sets for multiple sclerosis to specify functioning. Mult Scler. 2008;14(2):252-4.
5. National Institute for Clinical Excellence (NICE). Guidance for the management of MS. In: Multiple Sclerosis: national clinical guideline for diagnosis and management in primary and secondary care. London: NICE; 2003.
6. Multiple Sclerosis International Federation (MSIF). Principles to promote the quality of life of people with multiple sclerosis. London: Multiple Sclerosis International Federation; 2005.
7. Platform ME, editor. Recommendations on rehabilitation services for persons with multiple sclerosis in Europe. Genoa: Associazione Italiana Sclerosi Multipla; 2004.
8. Miller D, Rudick RA, Hutchinson M. Patient-centered outcomes: translating clinical ef fi cacy into bene fi ts on health-related quality of life. Neurology. 2010;74 Suppl 3:S24-35.
9. Thompson AJ, Toosy AT, Ciccarelli O. Pharmacological management of symptoms in multiple sclerosis: current approaches and future directions. Lancet Neurol. 2010;9(12):1182-99.
10. Lance JW. Symposium synopsis. in Spasticity: disordered motor control. Chicago: Year Book; 1980.
11. Pandyan AD, et al. Spasticity: clinical perceptions, neurological realities and meaningful measurement. Disabil Rehabil. 2005;27(1-2):2-6.
12. Rizzo MA, et al. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589-95.
13. Paisley S, et al. Clinical effectiveness of oral treatments for spasticity in multiple sclerosis: a systematic review. Mult Scler. 2002;8(4):319-29.
14. Paty DW, Ebers GC. Clinical features. In: Paty DW, Ebers GC, editors. Multiple sclerosis. Philadelphia: F. A. Davis; 1998. p. 135-92.
15. Francis HP, et al. Does reducing spasticity translate into functional bene fi t? An exploratory meta-analysis. J Neurol Neurosurg Psychiatry. 2004;75(11):1547-51.
16. Stevenson VL. Oral medication. In: Stevenson VL, Jarrett L, editors. Spasticity management: a practical multidisciplinary guide. London: Informa Healthcare; 2006. p. 59-70.
17. Paty DW, Hashimoto SA, Ebers GC. Management of multiple sclerosis and interpretation of clinical trials. In: Paty DW, Ebers GC, editors. Multiple sclerosis. Philadelphia: F. A. Davis; 1998. p. 427-519.
18. Rosche J, et al. The effects of therapy on spasticity utilizing a motorized exercise-cycle. Spinal Cord. 1997;35(3):176-8.
19. Kakebeeke TH, Lechner HE, Knapp PA. The effect of passive cycling movements on spasticity after spinal cord injury: preliminary results. Spinal Cord. 2005;43(8):483-8.
20. Nuyens GE, et al. Reduction of spastic hypertonia during repeated passive knee movements in stroke patients. Arch Phys Med Rehabil. 2002;83(7):930-5.
21. Schmit BD, Dewald JP, Rymer WZ. Stretch re fl ex adaptation in elbow fl exors during repeated passive movements in unilateral brain-injured patients. Arch Phys Med Rehabil. 2000;81(3): 269-78.
22. Katalinic OM, et al. Stretch for the treatment and prevention of contractures. Cochrane Database Syst Rev. 2010;(9):CD007455.
23. Gao F, et al. Effects of repeated ankle stretching on calf muscle-tendon and ankle biomechanical properties in stroke survivors. Clin Biomech (Bristol, Avon). 2011;26(5):516-22.
24. Katalinic OM, Harvey LA, Herbert RD. Effectiveness of stretch for the treatment and prevention of contractures in people with neurological conditions: a systematic review. Phys Ther. 2011;91(1):11-24.
25. White LJ, et al. Resistance training improves strength and functional capacity in persons with multiple sclerosis. Mult Scler. 2004;10(6):668-74.
26. Odeen I, Knutsson E. Evaluation of the effects of muscle stretch and weight load in patients with spastic paraplegia. Scand J Rehabil Med. 1981;13(4):117-21.
27. Bohannon RW. Tilt table standing for reducing spasticity after spinal cord injury. Arch Phys Med Rehabil. 1993;74(10):1121-2.
28. Rietberg MB, et al. Exercise therapy for multiple sclerosis. Cochrane Database Syst Rev. 2005;(1):CD003980.
29. Lockley LJ, Buchanan K. Physical management of spasticity. In: Stevenson VL, Jarrett L, editors. Spasticity management: a practical multidisciplinary guide. London: Informa Healthcare; 2006. p. 37-58.
30. Stevenson VL. Rehabilitation in practice: spasticity management. Clin Rehabil. 2010;24(4): 293-304.
31. Dalgas U, et al. Muscle fi ber size increases following resistance training in multiple sclerosis. Mult Scler. 2010;16(11):1367-76.
32. Dalgas U, et al. Fatigue, mood and quality of life improve in MS patients after progressive resistance training. Mult Scler. 2010;16(4):480-90.
33. Golzari Z, et al. Combined exercise training reduces IFN-gamma and IL-17 levels in the plasma and the supernatant of peripheral blood mononuclear cells in women with multiple sclerosis. Int Immunopharmacol. 2010;10(11):1415-9.
34. Mori F, et al. Transcranial magnetic stimulation primes the effects of exercise therapy in multiple sclerosis. J Neurol. 2011;258(7):1281-7.
35. Centonze D, et al. Repetitive transcranial magnetic stimulation of the motor cortex ameliorates spasticity in multiple sclerosis. Neurology. 2007;68(13):1045-50.
36. Mori F, et al. Effects of intermittent theta burst stimulation on spasticity in patients with multiple sclerosis. Eur J Neurol. 2010;17(2):295-300.
37. Nielsen JF, Sinkjaer T, Jakobsen J. Treatment of spasticity with repetitive magnetic stimulation; a double-blind placebo-controlled study. Mult Scler. 1996;2(5):227-32.
38. Bute fi sch CM, et al. Mechanisms of use-dependent plasticity in the human motor cortex. Proc Natl Acad Sci USA. 2000;97(7):3661-5.
39. Holtmaat A, Svoboda K. Experience-dependent structural synaptic plasticity in the mammalian brain. Nat Rev Neurosci. 2009;10(9):647-58.
40. Cooke SF, Bliss TV. Plasticity in the human central nervous system. Brain. 2006;129(Pt 7): 1659-73.
41. Ratchford JN, et al. A pilot study of functional electrical stimulation cycling in progressive multiple sclerosis. NeuroRehabilitation. 2010;27(2):121-8.
42. Barrett CL, et al. A randomized trial to investigate the effects of functional electrical stimulation and therapeutic exercise on walking performance for people with multiple sclerosis. Mult Scler. 2009;15(4):493-504.
43. Everaert DG, et al. Does functional electrical stimulation for foot drop strengthen corticospinal connections? Neurorehabil Neural Repair. 2010;24(2):168-77.
44. Shakespeare DT, Boggild M, Young C. Anti-spasticity agents for multiple sclerosis. Cochrane Database Syst Rev. 2003;(4):CD001332.
45. Hobart JC, et al. Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol. 2007;6(12):1094-105.
46. Hattab JR. Review of European clinical trials with baclofen. In: Feldman RG, Young RR, Koella WP, editors. Spasticity: disordered motor control. Chicago: Year Book; 1980. p. 71-85.
47. A double-blind, placebo-controlled trial of tizanidine in the treatment of spasticity caused by multiple sclerosis. United Kingdom Tizanidine Trial Group. Neurology. 1994;44(11 Suppl 9):S70-8.
48. Nance PW, et al. Ef fi cacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology. 1994;44(11 Suppl 9):S44-51; discussion S51-2.
49. Smith C, et al. Tizanidine treatment of spasticity caused by multiple sclerosis: results of a double-blind, placebo-controlled trial. US Tizanidine Study Group. Neurology. 1994;44 (11 Suppl 9):S34-42; discussion S42-3.
50. Groves L, Shellenberger MK, Davis CS. Tizanidine treatment of spasticity: a meta-analysis of controlled, double-blind, comparative studies with baclofen and diazepam. Adv Ther. 1998;15(4):241-51.
51. Wagstaff AJ, Bryson HM. Tizanidine. A review of its pharmacology, clinical ef fi cacy and tolerability in the management of spasticity associated with cerebral and spinal disorders. Drugs. 1997;53(3):435-52.
52. Krause T, et al. Dantrolene - a review of its pharmacology, therapeutic use and new developments. Anaesthesia. 2004;59(4):364-73.
53. Beard S, Hunn A, Wight J. Treatments for spasticity and pain in multiple sclerosis: a systematic review. Health Technol Assess. 2003;7(40):iii, ix-x, 1-111.
54. Mueller ME, et al. Gabapentin for relief of upper motor neuron symptoms in multiple sclerosis. Arch Phys Med Rehabil. 1997;78(5):521-4.
55. Cutter NC, et al. Gabapentin effect on spasticity in multiple sclerosis: a placebo-controlled, randomized trial. Arch Phys Med Rehabil. 2000;81(2):164-9.
56. Formica A, et al. Gabapentin for spasticity: a randomized, double-blind, placebo-controlled trial. Med Clin (Barc). 2005;124(3):81-5.
57. Fink K, et al. Inhibition of neuronal Ca(2+) in fl ux by gabapentin and pregabalin in the human neocortex. Neuropharmacology. 2002;42(2):229-36.
58. Bradley LJ, Kirker SG. Pregabalin in the treatment of spasticity: a retrospective case series. Disabil Rehabil. 2008;30(16):1230-2.
59. Rigo JM, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136(5):659-72.
60. Bedlack RS, et al. Open-label pilot trial of levetiracetam for cramps and spasticity in patients with motor neuron disease. Amyotroph Lateral Scler. 2009;10(4):210-5.
61. Ruegg SJ, Steck AJ, Fuhr P. Levetiracetam improves paroxysmal symptoms in a patient with stiff-person syndrome. Neurology. 2004;62(2):338.
62. Lashch N, Avakian GN. The use of midokalm in patients with multiple sclerosis. Zh Nevrol Psikhiatr Im SS Korsakova. 2000;100(6):24-8.
63. Stamenova P, et al. A randomized, double-blind, placebo-controlled study of the ef fi cacy and safety of tolperisone in spasticity following cerebral stroke. Eur J Neurol. 2005;12(6):453-61.
64. Bresolin N, Zucca C, Pecori A. Ef fi cacy and tolerability of eperisone in patients with spastic palsy: a cross-over, placebo-controlled dose-ranging trial. Eur Rev Med Pharmacol Sci. 2009;13(5):365-70.
65. Bresolin N, Zucca C, Pecori A. Ef fi cacy and tolerability of eperisone and baclofen in spastic palsy: a double-blind randomized trial. Adv Ther. 2009;26(5):563-73.
66. Adams IB, Martin BR. Cannabis: pharmacology and toxicology in animals and humans. Addiction. 1996;91(11):1585-614.
67. Gaoni Y, Mechoulam R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-7.
68. Tsou K, et al. Immunohistochemical distribution of cannabinoid CB1 receptors in the rat central nervous system. Neuroscience. 1998;83(2):393-411.
69. Herkenham M, et al. Cannabinoid receptor localization in brain. Proc Natl Acad Sci USA. 1990;87(5):1932-6.
70. Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83(3):1017-66.
71. Van Sickle MD, et al. Identi fi cation and functional characterization of brainstem cannabinoid CB2 receptors. Science. 2005;310(5746):329-32.
72. Skaper SD, et al. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed postglutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc Natl Acad Sci USA. 1996;93(9):3984-9.
73. Alger BE. Retrograde signaling in the regulation of synaptic transmission: focus on endocannabinoids. Prog Neurobiol. 2002;68(4):247-86.
74. Kreitzer AC, Regehr WG. Retrograde signaling by endocannabinoids. Curr Opin Neurobiol. 2002;12(3):324-30.
75. Berrendero F, et al. Changes in cannabinoid CB(1) receptors in striatal and cortical regions of rats with experimental allergic encephalomyelitis, an animal model of multiple sclerosis. Synapse. 2001;41(3):195-202.
76. Baker D, et al. Cannabinoids control spasticity and tremor in a multiple sclerosis model. Nature. 2000;404(6773):84-7.
77. Baker D, et al. Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J. 2001;15(2):300-2.
78. Baker D, Pryce G. The endocannabinoid system and multiple sclerosis. Curr Pharm Des. 2008;14(23):2326-36.
79. Chong MS, et al. Cannabis use in patients with multiple sclerosis. Mult Scler. 2006;12(5): 646-51.
80. Clark AJ, et al. Patterns of cannabis use among patients with multiple sclerosis. Neurology. 2004;62(11):2098-100.
81. Campbell FA, et al. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ. 2001;323(7303):13-6.
82. Zajicek JP, et al. Cannabinoids in multiple sclerosis (CAMS) study: safety and ef fi cacy data for 12 months follow up. J Neurol Neurosurg Psychiatry. 2005;76(12):1664-9.
83. Mal fi tano AM, Proto MC, Bifulco M. Cannabinoids in the management of spasticity associated with multiple sclerosis. Neuropsychiatr Dis Treat. 2008;4(5):847-53.
84. Lakhan SE, Rowland M. Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review. BMC Neurol. 2009;9:59.
85. Smith PF. New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids. Ther Clin Risk Manag. 2010;6:59-63.
86. Wade DT, et al. Meta-analysis of the ef fi cacy and safety of Sativex (nabiximols), on spasticity in people with multiple sclerosis. Mult Scler. 2010;16(6):707-14.
87. Hobart JC, et al. Getting the measure of spasticity in multiple sclerosis: the Multiple Sclerosis Spasticity Scale (MSSS-88). Brain. 2006;129(Pt 1):224-34.
88. Zajicek JP, Apostu VI. Role of cannabinoids in multiple sclerosis. CNS Drugs. 2011;25(3): 187-201.
89. Honarmand K, et al. Effects of cannabis on cognitive function in patients with multiple sclerosis. Neurology. 2011;76(13):1153-60.
90. Dolly JO, Aoki KR. The structure and mode of action of different botulinum toxins. Eur J Neurol. 2006;13 Suppl 4:1-9.
91. Ward AB. Spasticity treatment with botulinum toxins. J Neural Transm. 2008;115(4):607-16.
92. Kabus C, et al. Botulinum toxin in patients with multiple sclerosis. J Neurol. 2006;253 Suppl 1:I26-8.
93. Habek M, et al. The place of the botulinum toxin in the management of multiple sclerosis. Clin Neurol Neurosurg. 2010;112(7):592-6.
94. Giovannelli M, et al. Early physiotherapy after injection of botulinum toxin increases the bene fi cial effects on spasticity in patients with multiple sclerosis. Clin Rehabil. 2007;21(4):331-7.
95. Borg J, et al. Rationale and design of a multicentre, double-blind, prospective, randomized, European and Canadian study: evaluating patient outcomes and costs of managing adults with post-stroke focal spasticity. J Rehabil Med. 2011;43(1):15-22.
96. Burbaud P, et al. Botulinum toxin treatment in neurological practice: how much does it really cost? A prospective cost-effectiveness study. J Neurol. 2011;258(9):1670-5.
97. Elovic EP, et al. Chemodenervation and nerve blocks in the diagnosis and management of spasticity and muscle overactivity. PM R. 2009;1(9):842-51.
98. Yelnik AP, et al. How to clinically assess and treat muscle overactivity in spastic paresis. J Rehabil Med. 2010;42(9):801-7.
99. Bensmail D, et al. Effect of intrathecal baclofen on sleep and respiratory function in patients with spasticity. Neurology. 2006;67(8):1432-6.
100. Boviatsis EJ, et al. Functional outcome of intrathecal baclofen administration for severe spasticity. Clin Neurol Neurosurg. 2005;107(4):289-95.
101. Zahavi A, et al. Long term effect (more than fi ve years) of intrathecal baclofen on impairment, disability, and quality of life in patients with severe spasticity of spinal origin. J Neurol Neurosurg Psychiatry. 2004;75(11):1553-7.
102. Rekand T, Gronning M. Treatment of spasticity related to multiple sclerosis with intrathecal baclofen: a long-term follow-up. J Rehabil Med. 2011;43(6):511-4.
103. Schuele SU, et al. Incidence of seizures in patients with multiple sclerosis treated with intrathecal baclofen. Neurology. 2005;64(6):1086-7.
104. Cooper JA, Ridley B. Response of intrathecal baclofen resistance to dose reduction. Neurology. 2006;67(8):1495-6.
105. Kelly RE, Gautier Smith PC. Intrathecal phenol in the treatment of re fl ex spasms and spasticity. Lancet. 1959;274(7112):1102-5.
106. Maher RM. Relief of pain in incurable cancer. Lancet. 1955;265(6853):18-20.
107. Jarrett L, Nandi P, Thompson AJ. Managing severe lower limb spasticity in multiple sclerosis: does intrathecal phenol have a role? J Neurol Neurosurg Psychiatry. 2002;73(6):705-9.
108. Boop FA. Evolution of the neurosurgical management of spasticity. J Child Neurol. 2001;16(1):54-7.
109. Foerster O. On the indications and results of the excision of posterior spinal nerve roots in men. Surg Gynecol Obstet. 1913;16:463-74.
110. Sherrington C. The integrative action of the central nervous system. London: Archibald Constable; 1906.
111. Gros C, et al. La radicotomie selective posterieure dans le traitement neurochirurgical de l'hypertonie pyramidale. Neurochirurgie. 1967;13:505-18.
112. Salame K, et al. Surgical treatment of spasticity by selective posterior rhizotomy: 30 years experience. Isr Med Assoc J. 2003;5(8):543-6.
113. Maarrawi J, et al. Long-term functional results of selective peripheral neurotomy for the treatment of spastic upper limb: prospective study in 31 patients. J Neurosurg. 2006;104(2): 215-25.
114. Sindou M, Mertens P. Selective neurotomy of the tibial nerve for treatment of the spastic foot. Neurosurgery. 1988;23(6):738-44.
115. O'Connor AB, et al. Pain associated with multiple sclerosis: systematic review and proposed classi fi cation. Pain. 2008;137(1):96-111.
116. Hirsh AT, et al. Prevalence and impact of pain in multiple sclerosis: physical and psychologic contributors. Arch Phys Med Rehabil. 2009;90(4):646-51.
117. Brichetto G, et al. Symptomatic medication use in multiple sclerosis. Mult Scler. 2003;9(5): 458-60.
118. Moulin DE, Foley KM, Ebers GC. Pain syndromes in multiple sclerosis. Neurology. 1988;38(12):1830-4.
119. Osterberg A, Boivie J, Thuomas KA. Central pain in multiple sclerosis - prevalence and clinical characteristics. Eur J Pain. 2005;9(5):531-42.
120. Vermote R, Ketelaer P, Carton H. Pain in multiple sclerosis patients. A prospective study using the Mc Gill Pain Questionnaire. Clin Neurol Neurosurg. 1986;88(2):87-93.
121. Boneschi FM, et al. Lifetime and actual prevalence of pain and headache in multiple sclerosis. Mult Scler. 2008;14(4):514-21.
122. Solaro C, et al. The prevalence of pain in multiple sclerosis: a multicenter cross-sectional study. Neurology. 2004;63(5):919-21.
123. Hadjimichael O, et al. Persistent pain and uncomfortable sensations in persons with multiple sclerosis. Pain. 2007;127(1-2):35-41.
124. Ehde DM, et al. Chronic pain in a large community sample of persons with multiple sclerosis. Mult Scler. 2003;9(6):605-11.
125. Brochet B, et al. Pain and quality of life in the early stages after multiple sclerosis diagnosis: a 2-year longitudinal study. Clin J Pain. 2009;25(3):211-7.
126. Svendsen KB, et al. Pain in patients with multiple sclerosis: a population-based study. Arch Neurol. 2003;60(8):1089-94.
127. Putzki N, Katsarava Z. Headache in multiple sclerosis. Curr Pain Headache Rep. 2010;14(4): 316-20.
128. Kister I, et al. Tension-type headache and migraine in multiple sclerosis. Curr Pain Headache Rep. 2010;14(6):441-8.
129. Welch KM, et al. Periaqueductal gray matter dysfunction in migraine: cause or the burden of illness? Headache. 2001;41(7):629-37.
130. Knight YE, Goadsby PJ. The periaqueductal grey matter modulates trigeminovascular input: a role in migraine? Neuroscience. 2001;106(4):793-800.
131. Pollmann W, Feneberg W. Current management of pain associated with multiple sclerosis. CNS Drugs. 2008;22(4):291-324.
132. Treede RD, et al. Neuropathic pain: rede fi nition and a grading system for clinical and research purposes. Neurology. 2008;70(18):1630-5.
133. Grasso MG, et al. Pain in multiple sclerosis: a clinical and instrumental approach. Mult Scler. 2008;14(4):506-13.
134. Attal N, et al. EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol. 2006;13(11):1153-69.
135. Tan T, et al. Pharmacological management of neuropathic pain in non-specialist settings: summary of NICE guidance. BMJ. 2010;340:c1079.
136. Rahn EJ, Hohmann AG. Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedside. Neurotherapeutics. 2009;6(4):713-37.
137. Iskedjian M, et al. Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain. Curr Med Res Opin. 2007;23(1):17-24.
138. Karst M, Wippermann S, Ahrens J. Role of cannabinoids in the treatment of pain and (painful) spasticity. Drugs. 2010;70(18):2409-38.
139. Rowbotham MC, et al. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med. 2003;348(13):1223-32.
140. Breuer B, et al. A randomized, double-blind, placebo-controlled, two-period, crossover, pilot trial of lamotrigine in patients with central pain due to multiple sclerosis. Clin Ther. 2007;29(9):2022-30.
141. Kalman S, et al. Morphine responsiveness in a group of well-de fi ned multiple sclerosis patients: a study with i.v. morphine. Eur J Pain. 2002;6(1):69-80.
142. Chitsaz A, et al. Sensory complaints of the upper extremities in multiple sclerosis: relative ef fi cacy of nortriptyline and transcutaneous electrical nerve stimulation. Clin J Pain. 2009;25(4):281-5.
143. Kumar K, Hunter G, Demeria D. Spinal cord stimulation in treatment of chronic benign pain: challenges in treatment planning and present status, a 22-year experience. Neurosurgery. 2006;58(3):481-96; discussion 481-96.
144. Osenbach RK. Motor cortex stimulation for intractable pain. Neurosurg Focus. 2006;21(6):E7.
145. Levy R, Deer TR, Henderson J. Intracranial neurostimulation for pain control: a review. Pain Physician. 2010;13(2):157-65.
146. Patwardhan RV, et al. Neurosurgical treatment of multiple sclerosis. Neurol Res. 2006;28(3): 320-5.
147. Sadiq SA, Poopatana CA. Intrathecal baclofen and morphine in multiple sclerosis patients with severe pain and spasticity. J Neurol. 2007;254(10):1464-5.
148. Dahm PO, et al. Long-term intrathecal (i.t.) infusion of bupivacaine relieved intractable pain and spasticity in a patient with multiple sclerosis. Eur J Pain. 1998;2(1):81-5.
149. Solaro C, Tanganelli P. Tiagabine for treating painful tonic spasms in multiple sclerosis: a pilot study. J Neurol Neurosurg Psychiatry. 2004;75(2):341.
150. Hawker K, Frohman E, Racke M. Levetiracetam for phasic spasticity in multiple sclerosis. Arch Neurol. 2003;60(12):1772-4.
151. Solaro C, et al. Gabapentin is effective in treating nocturnal painful spasms in multiple sclerosis. Mult Scler. 2000;6(3):192-3.
152. Morgan JC, Hess DC, Sethi KD. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2004;62(11):2143; author reply 2143.
153. Restivo DA, et al. Botulinum toxin treatment of painful tonic spasms in multiple sclerosis. Neurology. 2003;61(5):719-20.
154. Sakurai M, Kanazawa I. Positive symptoms in multiple sclerosis: their treatment with sodium channel blockers, lidocaine and mexiletine. J Neurol Sci. 1999;162(2):162-8.
155. Putzki N, et al. Prevalence of migraine, tension-type headache and trigeminal neuralgia in multiple sclerosis. Eur J Neurol. 2009;16(2):262-7.
156. Rushton JG, Olafson RA. Trigeminal neuralgia associated with multiple sclerosis: report of 35 cases. Arch Neurol. 1965;13(4):383-6.
157. Love S, Gradidge T, Coakham HB. Trigeminal neuralgia due to multiple sclerosis: ultrastructural fi ndings in trigeminal rhizotomy specimens. Neuropathol Appl Neurobiol. 2001;27(3):238-44.
158. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain. 2001;124 (Pt 12):2347-60.
159. Cruccu G, et al. Trigeminal neuralgia and pain related to multiple sclerosis. Pain. 2009;143(3):186-91.
160. Espir ML, Millac P. Treatment of paroxysmal disorders in multiple sclerosis with carbamazepine (Tegretol). J Neurol Neurosurg Psychiatry. 1970;33(4):528-31.
161. Solaro C, et al. Antiepileptic medications in multiple sclerosis: adverse effects in a three-year follow-up study. Neurol Sci. 2005;25(6):307-10.
162. Ramsaransing G, Zwanikken C, De Keyser J. Worsening of symptoms of multiple sclerosis associated with carbamazepine. BMJ. 2000;320(7242):1113.
163. Lunardi G, et al. Clinical effectiveness of lamotrigine and plasma levels in essential and symptomatic trigeminal neuralgia. Neurology. 1997;48(6):1714-7.
164. Leandri M, et al. Lamotrigine in trigeminal neuralgia secondary to multiple sclerosis. J Neurol. 2000;247(7):556-8.
165. Solaro C, et al. Low-dose gabapentin combined with either lamotrigine or carbamazepine can be useful therapies for trigeminal neuralgia in multiple sclerosis. Eur Neurol. 2000;44(1):45-8.
166. Khan OA. Gabapentin relieves trigeminal neuralgia in multiple sclerosis patients. Neurology. 1998;51(2):611-4.
167. Solaro C, et al. An open-label trial of gabapentin treatment of paroxysmal symptoms in multiple sclerosis patients. Neurology. 1998;51(2):609-11.
168. Zvartau-Hind M, et al. Topiramate relieves refractory trigeminal neuralgia in MS patients. Neurology. 2000;55(10):1587-8.
169. Solaro C, et al. Topiramate relieves idiopathic and symptomatic trigeminal neuralgia. J Pain Symptom Manage. 2001;21(5):367-8.
170. DMKG study group. Misoprostol in the treatment of trigeminal neuralgia associated with multiple sclerosis. J Neurol. 2003;250(5):542-5.
171. Reder AT, Arnason BG. Trigeminal neuralgia in multiple sclerosis relieved by a prostaglandin E analogue. Neurology. 1995;45(6):1097-100.
172. Zakrzewska JM, et al. Patient reports of satisfaction after microvascular decompression and partial sensory rhizotomy for trigeminal neuralgia. Neurosurgery. 2005;56(6):1304-11; discussion 1311-2.
173. Brisman R. Trigeminal neuralgia and multiple sclerosis. Arch Neurol. 1987;44(4):379-81.
174. Eldridge PR, et al. Microvascular decompression for trigeminal neuralgia in patients with multiple sclerosis. Stereotact Funct Neurosurg. 2003;81(1-4):57-64.
175. Athanasiou TC, et al. Some patients with multiple sclerosis have neurovascular compression causing their trigeminal neuralgia and can be treated effectively with MVD: report of fi ve cases. Br J Neurosurg. 2005;19(6):463-8.
176. Broggi G, et al. Operative fi ndings and outcomes of microvascular decompression for trigeminal neuralgia in 35 patients affected by multiple sclerosis. Neurosurgery. 2004;55(4):830-8; discussion 838-9.
177. Broggi G, et al. Role of microvascular decompression in trigeminal neuralgia and multiple sclerosis. Lancet. 1999;354(9193):1878-9.
178. Broggi G, et al. Microvascular decompression for trigeminal neuralgia: comments on a series of 250 cases, including 10 patients with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;68(1):59-64.
179. Sandell T, Eide PK. The effect of microvascular decompression in patients with multiple sclerosis and trigeminal neuralgia. Neurosurgery. 2010;67(3):749-53; discussion 753-4.
180. Zakrzewska JM, McMillan R. Trigeminal neuralgia: the diagnosis and management of this excruciating and poorly understood facial pain. Postgrad Med J. 2011;87(1028):410-6.
181. Harries AM, Mitchell RD. Percutaneous glycerol rhizotomy for trigeminal neuralgia: safety and ef fi cacy of repeat procedures. Br J Neurosurg. 2011;25(2):268-72.
182. Pickett GE, Bisnaire D, Ferguson GG. Percutaneous retrogasserian glycerol rhizotomy in the treatment of tic douloureux associated with multiple sclerosis. Neurosurgery. 2005;56(3):537- 45; discussion 537-45.
183. Kanpolat Y, et al. Percutaneous controlled radiofrequency rhizotomy in the management of patients with trigeminal neuralgia due to multiple sclerosis. Acta Neurochir (Wien). 2000;142(6):685-9; discussion 689-90.
184. Zorro O, et al. Gamma knife radiosurgery for multiple sclerosis-related trigeminal neuralgia. Neurology. 2009;73(14):1149-54.
185. Verheul JB, et al. Gamma Knife surgery for trigeminal neuralgia: a review of 450 consecutive cases. J Neurosurg. 2010;113(Suppl):160-7.
186. Nurmikko TJ. Pathophysiology of MS-related trigeminal neuralgia. Pain. 2009;143(3):165-6.
187. Minagar A, Sheremata WA. Glossopharyngeal neuralgia and MS. Neurology. 2000;54(6): 1368-70.
188. Al-Araji AH, Oger J. Reappraisal of Lhermitte's sign in multiple sclerosis. Mult Scler. 2005;11(4):398-402.
189. Rudick R, Goodkin D. Multiple sclerosis therapeutics. London: Martin Dunitz Ltd.; 1999.
190. Hemmett L, et al. What drives quality of life in multiple sclerosis? QJM. 2004;97(10): 671-6.
191. Fowler CJ, Grif fi ths D, de Groat WC. The neural control of micturition. Nat Rev Neurosci. 2008;9(6):453-66.
192. Betts CD, D'Mellow MT, Fowler CJ. Urinary symptoms and the neurological features of bladder dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1993;56(3): 245-50.
193. Fowler CJ, et al. A UK consensus on the management of the bladder in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80(5):470-7.
194. de Seze M, et al. The neurogenic bladder in multiple sclerosis: review of the literature and proposal of management guidelines. Mult Scler. 2007;13(7):915-28.
195. Khan F, et al. A randomised controlled trial: outcomes of bladder rehabilitation in persons with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2010;81(9):1033-8.
196. O'Riordan JI, et al. Do alpha-blockers have a role in lower urinary tract dysfunction in multiple sclerosis? J Urol. 1995;153(4):1114-6.
197. Prasad RS, Smith SJ, Wright H. Lower abdominal pressure versus external bladder stimulation to aid bladder emptying in multiple sclerosis: a randomized controlled study. Clin Rehabil. 2003;17(1):42-7.
198. McConnell JD, et al. The long-term effect of doxazosin, fi nasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25): 2387-98.
199. National Institute for Health and Clinical Excellence. Infection control. Prevention of healthcare- associated infection in primary and community care. London: National Institute for Health and Clinical Excellence; 2003.
200. Lekka E, Lee LK. Successful treatment with intradetrusor Botulinum-A toxin for urethral urinary leakage (catheter bypassing) in patients with end-staged multiple sclerosis and indwelling suprapubic catheters. Eur Urol. 2006;50(4):806-9; discussion 809-10.
201. Ethans KD, et al. Ef fi cacy and safety of tolterodine in people with neurogenic detrusor overactivity. J Spinal Cord Med. 2004;27(3):214-8.
202. Gajewski JB, Awad SA. Oxybutynin versus propantheline in patients with multiple sclerosis and detrusor hyperre fl exia. J Urol. 1986;135(5):966-8.
203. Amend B, et al. Effective treatment of neurogenic detrusor dysfunction by combined highdosed antimuscarinics without increased side-effects. Eur Urol. 2008;53(5):1021-8.
204. Weese DL, et al. Intravesical oxybutynin chloride: experience with 42 patients. Urology. 1993;41(6):527-30.
205. Fader M, et al. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol. 2007;177(1):208-13; discussion 213.
206. Herschorn S, et al. Ef fi cacy of botulinum toxin a injection for neurogenic detrusor overactivity and urinary incontinence: a randomized, double-blind trial. J Urol. 2011;185(6):2229-35.
207. Khan S, et al. Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxin-A for detrusor overactivity in patients with multiple sclerosis. J Urol. 2011;185(4):1344-9.
208. Bosma R, et al. Ef fi cacy of desmopressin in patients with multiple sclerosis suffering from bladder dysfunction: a meta-analysis. Acta Neurol Scand. 2005;112(1):1-5.
209. British National Formulary 61. London: BMJ Group and Pharma Press; 2011.
210. Reynard JM, et al. A novel therapy for nocturnal polyuria: a double-blind randomized trial of frusemide against placebo. Br J Urol. 1998;81(2):215-8.
211. Freeman RM, et al. The effect of cannabis on urge incontinence in patients with multiple sclerosis: a multicentre, randomised placebo-controlled trial (CAMS-LUTS). Int Urogynecol J Pelvic Floor Dysfunct. 2006;17(6):636-41.
212. Brady CM, et al. An open-label pilot study of cannabis-based extracts for bladder dysfunction in advanced multiple sclerosis. Mult Scler. 2004;10(4):425-33.
213. Kavia RB, et al. Randomized controlled trial of Sativex to treat detrusor overactivity in multiple sclerosis. Mult Scler. 2010;16(11):1349-59.
214. Ruggieri Sr MR. Cannabinoids: potential targets for bladder dysfunction. Handb Exp Pharmacol. 2011;202:425-51.
215. Wiart L, et al. The effects of capsaicin on the neurogenic hyperre fl exic detrusor. A double blind placebo controlled study in patients with spinal cord disease. Preliminary results. Spinal Cord. 1998;36(2):95-9.
216. Kim JH, et al. Intravesical resiniferatoxin for refractory detrusor hyperre fl exia: a multicenter, blinded, randomized, placebo-controlled trial. J Spinal Cord Med. 2003;26(4):358-63.
217. Marinkovic SP, Gillen LM. Sacral neuromodulation for multiple sclerosis patients with urinary retention and clean intermittent catheterization. Int Urogynecol J Pelvic Floor Dysfunct. 2010;21(2):223-8.
218. Tjon Eng Soe SH, et al. Multiple sclerosis patients with bladder dysfunction have decreased symptoms after electro-acupuncture. Mult Scler. 2009;15(11):1376-7.
219. Kabay S, et al. The clinical and urodynamic results of a 3-month percutaneous posterior tibial nerve stimulation treatment in patients with multiple sclerosis-related neurogenic bladder dysfunction. Neurourol Urodyn. 2009;28(8):964-8.
220. Fjorback MV, et al. Event driven electrical stimulation of the dorsal penile/clitoral nerve for management of neurogenic detrusor overactivity in multiple sclerosis. Neurourol Urodyn. 2006;25(4):349-55.
221. Delong J, Tighiouart H, Stoffel J. Urinary diversion/reconstruction for cases of catheter intolerant secondary progressive multiple sclerosis with refractory urinary symptoms. J Urol. 2011;185(6):2201-6.
222. Betts CD, et al. Erectile dysfunction in multiple sclerosis. Associated neurological and neurophysiological de fi cits, and treatment of the condition. Brain. 1994;117(Pt 6):1303-10.
223. Zorzon M, et al. Sexual dysfunction in multiple sclerosis: a case-control study. I. Frequency and comparison of groups. Mult Scler. 1999;5(6):418-27.
224. Lilius HG, Valtonen EJ, Wikstrom J. Sexual problems in patients suffering from multiple sclerosis. J Chronic Dis. 1976;29(10):643-7.
225. O'Sullivan SS, Hardiman O. Detection rates of sexual dysfunction amongst patients with multiple sclerosis in an outpatient setting - can this be improved? Ir Med J. 2006;99(10): 304-6.
226. Zivadinov R, et al. Sexual dysfunction in multiple sclerosis: II. Correlation analysis. Mult Scler. 1999;5(6):428-31.
227. Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. Lancet. 2007;369(9560):512-25.
228. Fletcher SG, et al. Sexual dysfunction in patients with multiple sclerosis: a multidisciplinary approach to evaluation and management. Nat Clin Pract Urol. 2009;6(2):96-107.
229. Safarinejad MR. Evaluation of the safety and ef fi cacy of sildena fi l citrate for erectile dysfunction in men with multiple sclerosis: a double-blind, placebo controlled, randomized study. J Urol. 2009;181(1):252-8.
230. Fowler CJ, et al. A double blind, randomised study of sildena fi l citrate for erectile dysfunction in men with multiple sclerosis. J Neurol Neurosurg Psychiatry. 2005;76(5):700-5.
231. Pifarre P, et al. Sildena fi l (Viagra) ameliorates clinical symptoms and neuropathology in a mouse model of multiple sclerosis. Acta Neuropathol. 2011;121(4):499-508.
232. Lombardi G, Macchiarella A, Del Popolo G. Ef fi cacy and safety of tadala fi l for erectile dysfunction in patients with multiple sclerosis. J Sex Med. 2010;7(6):2192-200.
233. DasGupta R, Fowler CJ. Bladder, bowel and sexual dysfunction in multiple sclerosis: management strategies. Drugs. 2003;63(2):153-66.
234. Safarinejad MR. Midodrine for the treatment of organic anejaculation but not spinal cord injury: a prospective randomized placebo-controlled double-blind clinical study. Int J Impot Res. 2009;21(4):213-20.
235. Dasgupta R, et al. Ef fi cacy of sildena fi l in the treatment of female sexual dysfunction due to multiple sclerosis. J Urol. 2004;171(3):1189-93; discussion 1193.
236. Chia YW, et al. Prevalence of bowel dysfunction in patients with multiple sclerosis and bladder dysfunction. J Neurol. 1995;242(2):105-8.
237. Hinds JP, Eidelman BH, Wald A. Prevalence of bowel dysfunction in multiple sclerosis. A population survey. Gastroenterology. 1990;98(6):1538-42.
238. Sullivan SN, Ebers GC. Gastrointestinal dysfunction in multiple sclerosis. Gastroenterology. 1983;84(6):1640.
239. Hennessey A, et al. Urinary, faecal and sexual dysfunction in patients with multiple sclerosis. J Neurol. 1999;246(11):1027-32.
240. Nortvedt MW, et al. Prevalence of bladder, bowel and sexual problems among multiple sclerosis patients two to fi ve years after diagnosis. Mult Scler. 2007;13(1):106-12.
241. Wiesel PH, et al. Pathophysiology and management of bowel dysfunction in multiple sclerosis. Eur J Gastroenterol Hepatol. 2001;13(4):441-8.
242. Emmanuel A. Managing neurogenic bowel dysfunction. Clin Rehabil. 2010;24(6):483-8.
243. Muller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta analysis. Br Med J (Clin Res Ed). 1988;296(6622):615-7.
244. Wiesel PH, et al. Gut focused behavioural treatment (biofeedback) for constipation and faecal incontinence in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2000;69(2):240-3.
245. McClurg D, et al. Abdominal massage for the alleviation of constipation symptoms in people with multiple sclerosis: a randomized controlled feasibility study. Mult Scler. 2011;17(2):223-33.
246. House JG, Stiens SA. Pharmacologically initiated defecation for persons with spinal cord injury: effectiveness of three agents. Arch Phys Med Rehabil. 1997;78(10):1062-5.
247. Gill KP, et al. Defecography in multiple sclerosis patients with severe constipation. Radiology. 1994;191(2):553-6.
248. Emmanuel A. Review of the ef fi cacy and safety of transanal irrigation for neurogenic bowel dysfunction. Spinal Cord. 2010;48(9):664-73.
249. Preziosi G, Emmanuel A. Neurogenic bowel dysfunction: pathophysiology, clinical manifestations and treatment. Expert Rev Gastroenterol Hepatol. 2009;3(4):417-23.
250. Randell N, et al. Does a colostomy alter quality of life in patients with spinal cord injury? A controlled study. Spinal Cord. 2001;39(5):279-82.
251. Swingler RJ, Compston DA. The morbidity of multiple sclerosis. Q J Med. 1992;83(300): 325-37.
252. Alusi SH, et al. A study of tremor in multiple sclerosis. Brain. 2001;124(Pt 4):720-30.
253. Pittock SJ, et al. Prevalence of tremor in multiple sclerosis and associated disability in the Olmsted County population. Mov Disord. 2004;19(12):1482-5.
254. Koch M, et al. Tremor in multiple sclerosis. J Neurol. 2007;254(2):133-45.
255. Sandyk R, Dann LC. Weak electromagnetic fi elds attenuate tremor in multiple sclerosis. Int J Neurosci. 1994;79(3-4):199-212.
256. Dahlin-Webb SR. A weighted wrist cuff. Am J Occup Ther. 1986;40(5):363-4.
257. Aisen ML, et al. The effect of mechanical damping loads on disabling action tremor. Neurology. 1993;43(7):1346-50.
258. Armutlu K, Karabudak R, Nurlu G. Physiotherapy approaches in the treatment of ataxic multiple sclerosis: a pilot study. Neurorehabil Neural Repair. 2001;15(3):203-11.
259. Feys P, et al. Assistive technology to improve PC interaction for people with intention tremor. J Rehabil Res Dev. 2001;38(2):235-43.
260. Vergaro E, et al. Adaptive robot training for the treatment of incoordination in Multiple Sclerosis. J Neuroeng Rehabil. 2010;7:37.
261. Mills RJ, Yap L, Young CA. Treatment for ataxia in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD005029.
262. Henkin Y, Herishanu YO. Primidone as a treatment for cerebellar tremor in multiple sclerosis - two case reports. Isr J Med Sci. 1989;25(12):720-1.
263. Aisen ML, et al. Glutethimide treatment of disabling action tremor in patients with multiple sclerosis and traumatic brain injury. Arch Neurol. 1991;48(5):513-5.
264. Weiss N, et al. Attenuation of cerebellar tremor with implantation of an intrathecal baclofen pump: the role of gamma-aminobutyric acidergic pathways. Case report. J Neurosurg. 2003;99(4):768-71.
265. Schroeder A, et al. Successful treatment of cerebellar ataxia and tremor in multiple sclerosis with topiramate: a case report. Clin Neuropharmacol. 2010;33(6):317-8.
266. Sabra AF, et al. Treatment of action tremor in multiple sclerosis with isoniazid. Neurology. 1982;32(8):912-3.
267. Duquette P, Pleines J, du Souich P. Isoniazid for tremor in multiple sclerosis: a controlled trial. Neurology. 1985;35(12):1772-5.
268. Morrow J, et al. Isoniazid and action tremor in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1985;48(3):282-3.
269. Francis DA, Grundy D, Heron JR. The response to isoniazid of action tremor in multiple sclerosis and its assessment using polarised light goniometry. J Neurol Neurosurg Psychiatry. 1986;49(1):87-9.
270. Koller WC. Pharmacologic trials in the treatment of cerebellar tremor. Arch Neurol. 1984;41(3):280-1.
271. Feys P, et al. The effect of levetiracetam on tremor severity and functionality in patients with multiple sclerosis. Mult Scler. 2009;15(3):371-8.
272. Monaca-Charley C, et al. Double-blind crossover study with dolasetron mesilate, a 5-HT3 receptor antagonist in cerebellar syndrome secondary to multiple sclerosis. J Neurol. 2003;250(10):1190-4.
273. Hallett M, et al. Controlled trial of isoniazid therapy for severe postural cerebellar tremor in multiple sclerosis. Neurology. 1985;35(9):1374-7.
274. Bozek CB, et al. A controlled trial of isoniazid therapy for action tremor in multiple sclerosis. J Neurol. 1987;234(1):36-9.
275. Sechi GP, et al. Treatment of cerebellar tremors with carbamazepine: a controlled trial with long-term follow-up. Neurology. 1989;39(8):1113-5.
276. Rice GP, et al. Ondansetron, a 5-HT3 antagonist, improves cerebellar tremor. J Neurol Neurosurg Psychiatry. 1997;62(3):282-4.
277. Zajicek J, et al. Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial. Lancet. 2003;362(9395):1517-26.
278. Fox P, et al. The effect of cannabis on tremor in patients with multiple sclerosis. Neurology. 2004;62(7):1105-9.
279. Wade DT, et al. Do cannabis-based medicinal extracts have general or speci fi c effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10(4):434-41.
280. Yap L, Kouyialis A, Varma TR. Stereotactic neurosurgery for disabling tremor in multiple sclerosis: thalamotomy or deep brain stimulation? Br J Neurosurg. 2007;21(4):349-54.
281. Johnson RD, et al. Perioperative seizures following deep brain stimulation in patients with multiple sclerosis. Br J Neurosurg. 2010;24(3):289-90.
282. Jahanshahi M, et al. Effects on cognition of stereotactic lesional surgery for the treatment of tremor in multiple sclerosis. Behav Neurol. 2008;20(1-2):1-9.
283. Timmermann L, et al. Deep brain stimulation for tremor in multiple sclerosis: consensus recommendations of the German Deep Brain Stimulation Association. Nervenarzt. 2009;80(6):673-7.
284. Figved N, et al. Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. J Neurol Neurosurg Psychiatry. 2007;78(10):1097-102.
285. Patten SB, et al. Major depression in multiple sclerosis: a population-based perspective. Neurology. 2003;61(11):1524-7.
286. Chwastiak L, et al. Depressive symptoms and severity of illness in multiple sclerosis: epidemiologic study of a large community sample. Am J Psychiatry. 2002;159(11):1862-8.
287. Harel Y, Barak Y, Achiron A. Dysregulation of affect in multiple sclerosis: new phenomenological approach. Psychiatry Clin Neurosci. 2007;61(1):94-8.
288. Feinstein A. Mood disorders in multiple sclerosis and the effects on cognition. J Neurol Sci. 2006;245(1-2):63-6.
289. Demaree HA, Gaudino E, DeLuca J. The relationship between depressive symptoms and cognitive dysfunction in multiple sclerosis. Cogn Neuropsychiatry. 2003;8(3):161-71.
290. Figved N, et al. Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. Mult Scler. 2008;14(8):1084-90.
291. McGuigan C, Hutchinson M. Unrecognised symptoms of depression in a community-based population with multiple sclerosis. J Neurol. 2006;253(2):219-23.
292. Lincoln NB, et al. Evaluation of an adjustment group for people with multiple sclerosis and low mood: a randomized controlled trial. Mult Scler. 2011;17(10):1250-7.
293. Rigby SA, Thornton EW, Young CA. A randomized group intervention trial to enhance mood and self-ef fi cacy in people with multiple sclerosis. Br J Health Psychol. 2008;13 (Pt 4):619-31.
294. Dennison L, Moss-Morris R. Cognitive-behavioral therapy: what bene fi ts can it offer people with multiple sclerosis? Expert Rev Neurother. 2010;10(9):1383-90.
295. Thomas PW, et al. Psychological interventions for multiple sclerosis. Cochrane Database Syst Rev. 2006;(1):CD004431.
296. Koch MW, et al. Pharmacologic treatment of depression in multiple sclerosis. Cochrane Database Syst Rev. 2011;(2):CD007295.
297. Price A, et al. Antidepressants for the treatment of depression in neurological disorders: a systematic review and meta-analysis of randomised controlled trials. J Neurol Neurosurg Psychiatry. 2011;82(8):914-23.
298. Patten SB, Svenson LW, Metz LM. Psychotic disorders in MS: population-based evidence of an association. Neurology. 2005;65(7):1123-5.
299. Surridge D. An investigation into some psychiatric aspects of multiple sclerosis. Br J Psychiatry. 1969;115(524):749-64.
300. Kosmidis MH, et al. Psychotic features associated with multiple sclerosis. Int Rev Psychiatry. 2010;22(1):55-66.
301. Sechi GP, et al. Dexamethasone-induced schizoaffective-like state in multiple sclerosis: prophylaxis and treatment with carbamazepine. Clin Neuropharmacol. 1987;10(5):453-7.
302. Minden SL, Orav J, Schildkraut JJ. Hypomanic reactions to ACTH and prednisone treatment for multiple sclerosis. Neurology. 1988;38(10):1631-4.
303. Goeb JL, et al. Acute delirium, delusion, and depression during IFN-beta-1a therapy for multiple sclerosis: a case report. Clin Neuropharmacol. 2003;26(1):5-7.
304. Manfredi G, et al. Persistent interferon-ss-1b-induced psychosis in a patient with multiple sclerosis. Psychiatry Clin Neurosci. 2010;64(5):584-6.
305. Feinstein A, du Boulay G, Ron MA. Psychotic illness in multiple sclerosis. A clinical and magnetic resonance imaging study. Br J Psychiatry. 1992;161:680-5.
306. Chong SA, Ko SM. Clozapine treatment of psychosis associated with multiple sclerosis. Can J Psychiatry. 1997;42(1):90-1.
307. Safferman AZ, et al. The use of clozapine in neurologic disorders. J Clin Psychiatry. 1994;55(Suppl B):98-101.
308. Hussain A, Belderbos S. Risperidone depot in the treatment of psychosis associated with multiple sclerosis - a case report. J Psychopharmacol. 2008;22(8):925-6.
309. Davids E, Hartwig U, Gastpar M. Antipsychotic treatment of psychosis associated with multiple sclerosis. Prog Neuropsychopharmacol Biol Psychiatry. 2004;28(4):743-4.
310. Schiffer RB, Wineman NM, Weitkamp LR. Association between bipolar affective disorder and multiple sclerosis. Am J Psychiatry. 1986;143(1):94-5.
311. Paparrigopoulos T, et al. The neuropsychiatry of multiple sclerosis: focus on disorders of mood, affect and behaviour. Int Rev Psychiatry. 2010;22(1):14-21.
312. Feinstein A, et al. Prevalence and neurobehavioral correlates of pathological laughing and crying in multiple sclerosis. Arch Neurol. 1997;54(9):1116-21.
313. Pioro EP, et al. Dextromethorphan plus ultra low-dose quinidine reduces pseudobulbar affect. Ann Neurol. 2010;68(5):693-702.
314. Panitch HS, et al. Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis. Ann Neurol. 2006;59(5):780-7.
315. Schiffer RB, Herndon RM, Rudick RA. Treatment of pathologic laughing and weeping with amitriptyline. N Engl J Med. 1985;312(23):1480-2.
316. Iannaccone S, Ferini-Strambi L. Pharmacologic treatment of emotional lability. Clin Neuropharmacol. 1996;19(6):532-5.
317. Nahas Z, et al. Rapid response of emotional incontinence to selective serotonin reuptake inhibitors. J Neuropsychiatry Clin Neurosci. 1998;10(4):453-5.
318. Chiaravalloti ND, DeLuca J. Cognitive impairment in multiple sclerosis. Lancet Neurol. 2008;7(12):1139-51.
319. Portaccio E, et al. Neuropsychological and MRI measures predict short-term evolution in benign multiple sclerosis. Neurology. 2009;73(7):498-503.
320. Potagas C, et al. Cognitive impairment in different MS subtypes and clinically isolated syndromes. J Neurol Sci. 2008;267(1-2):100-6.
321. Amato MP, et al. Cognitive dysfunction in early-onset multiple sclerosis: a reappraisal after 10 years. Arch Neurol. 2001;58(10):1602-6.
322. Denney DR, Sworowski LA, Lynch SG. Cognitive impairment in three subtypes of multiple sclerosis. Arch Clin Neuropsychol. 2005;20(8):967-81.
323. Rao SM, et al. Cognitive dysfunction in multiple sclerosis. II. Impact on employment and social functioning. Neurology. 1991;41(5):692-6.
324. Jennekens-Schinkel A, et al. Cognition in patients with multiple sclerosis after four years. J Neurol Sci. 1990;99(2-3):229-47.
325. Kujala P, Portin R, Ruutiainen J. The progress of cognitive decline in multiple sclerosis. A controlled 3-year follow-up. Brain. 1997;120(Pt 2):289-97.
326. Fischer JS, et al. Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group. Ann Neurol. 2000;48(6): 885-92.
327. Patti F, et al. Effects of immunomodulatory treatment with subcutaneous interferon beta-1a on cognitive decline in mildly disabled patients with relapsing-remitting multiple sclerosis. Mult Scler. 2010;16(1):68-77.
328. Pliskin NH, et al. Improved delayed visual reproduction test performance in multiple sclerosis patients receiving interferon beta-1b. Neurology. 1996;47(6):1463-8.
329. Flechter S, et al. Cognitive dysfunction evaluation in multiple sclerosis patients treated with interferon beta-1b: an open-label prospective 1 year study. Isr Med Assoc J. 2007;9(6): 457-9.
330. Kappos L, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a fi rst clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet. 2007;370(9585):389-97.
331. Mattioli F, Stampatori C, Capra R. The effect of natalizumab on cognitive function in patients with relapsing-remitting multiple sclerosis: preliminary results of a 1-year follow-up study. Neurol Sci. 2011;32(1):83-8.
332. D'Intino G, et al. Cognitive de fi cit associated with cholinergic and nerve growth factor downregulation in experimental allergic encephalomyelitis in rats. Proc Natl Acad Sci USA. 2005;102(8):3070-5.
333. Krupp LB, et al. Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis. Neurology. 2011;76(17):1500-7.
334. Shaygannejad V, et al. Effects of rivastigmine on memory and cognition in multiple sclerosis. Can J Neurol Sci. 2008;35(4):476-81.
335. Villoslada P, et al. Memantine induces reversible neurologic impairment in patients with MS. Neurology. 2009;72(19):1630-3.
336. Lovera JF, et al. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010;16(6):715-23.
337. Geisler MW, et al. The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis. Arch Neurol. 1996;53(2):185-8.
338. Lovera J, et al. Ginkgo biloba for the improvement of cognitive performance in multiple sclerosis: a randomized, placebo-controlled trial. Mult Scler. 2007;13(3):376-85.
339. Morrow SA, et al. The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial. J Neurol. 2009;256(7):1095-102.
340. Oleen-Burkey M, Hadjimichael O, Vollmer T. Fatigue characteristics in multiple sclerosis: the North American Research Committee on Multiple Sclerosis (NARCOMS) survey. Health Qual Life Outcomes. 2008;6:100.
341. Krupp L. Fatigue is intrinsic to multiple sclerosis (MS) and is the most commonly reported symptom of the disease. Mult Scler. 2006;12(4):367-8.
342. Lerdal A, et al. A prospective study of patterns of fatigue in multiple sclerosis. Eur J Neurol. 2007;14(12):1338-43.
343. Smith MM, Arnett PA. Factors related to employment status changes in individuals with multiple sclerosis. Mult Scler. 2005;11(5):602-9.
344. Judica E, et al. Impact of fatigue on the ef fi cacy of rehabilitation in multiple sclerosis. J Neurol. 2011;258(5):835-9.
345. Veauthier C, et al. Fatigue in multiple sclerosis is closely related to sleep disorders: a polysomnographic cross-sectional study. Mult Scler. 2011;17(5):613-22.
346. Kaminska M, et al. Sleep disorders and fatigue in multiple sclerosis: evidence for association and interaction. J Neurol Sci. 2011;302(1-2):7-13.
347. Braley TJ, Chervin RD. Fatigue in multiple sclerosis: mechanisms, evaluation, and treatment. Sleep. 2010;33(8):1061-7.
348. Schwid SR, et al. A randomized controlled study of the acute and chronic effects of cooling therapy for MS. Neurology. 2003;60(12):1955-60.
349. van Kessel K, et al. A randomized controlled trial of cognitive behavior therapy for multiple sclerosis fatigue. Psychosom Med. 2008;70(2):205-13.
350. Thomas PW, et al. Multi-centre parallel arm randomised controlled trial to assess the effectiveness and cost-effectiveness of a group-based cognitive behavioural approach to managing fatigue in people with multiple sclerosis. BMC Neurol. 2010;10:43.
351. Piatkowski J, Kern S, Ziemssen T. Effect of BEMER magnetic fi eld therapy on the level of fatigue in patients with multiple sclerosis: a randomized, double-blind controlled trial. J Altern Complement Med. 2009;15(5):507-11.
352. Carvalho ML, et al. A randomized placebo-controlled cross-over study using a low frequency magnetic fi eld in the treatment of fatigue in multiple sclerosis. Mult Scler. 2012;18(1):82-9.
353. Metz LM, et al. The effect of immunomodulatory treatment on multiple sclerosis fatigue. J Neurol Neurosurg Psychiatry. 2004;75(7):1045-7.
354. Putzki N, et al. Multiple sclerosis associated fatigue during natalizumab treatment. J Neurol Sci. 2009;285(1-2):109-13.
355. Yildiz M, Tettenborn B, Putzki N. Multiple sclerosis-associated fatigue during disease-modifying treatment with natalizumab, interferon-beta and glatiramer acetate. Eur Neurol. 2011;65(4):231-2.
356. Multiple Sclerosis Council for Clinical Practice Guidelines. Fatigue and multiple sclerosis. Evidence-based management strategies for fatigue in multiple sclerosis. Washington: Paralyzed Veterans of America; 1998.
357. Branas P, et al. Treatments for fatigue in multiple sclerosis: a rapid and systematic review. Health Technol Assess. 2000;4(27):1-61.
358. Pucci E, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD002818.
359. Taus C, et al. Amantadine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2003;(2):CD002818.
360. Lange R, et al. Moda fi nil effects in multiple sclerosis patients with fatigue. J Neurol. 2009;256(4):645-50.
361. Moller F, et al. HAGIL (Hamburg Vigil Study): a randomized placebo-controlled doubleblind study with moda fi nil for treatment of fatigue in patients with multiple sclerosis. Mult Scler. 2011;17(8):1002-9.
362. Weinshenker BG, et al. A double-blind, randomized, crossover trial of pemoline in fatigue associated with multiple sclerosis. Neurology. 1992;42(8):1468-71.
363. Krupp LB, et al. Fatigue therapy in multiple sclerosis: results of a double-blind, randomized, parallel trial of amantadine, pemoline, and placebo. Neurology. 1995;45(11):1956-61.
364. Goodman AD, et al. Fampridine-SR in multiple sclerosis: a randomized, double-blind, placebo- controlled, dose-ranging study. Mult Scler. 2007;13(3):357-68.
365. Solari JJ, Pozzi AG, Ceballos NR. Seasonal changes in the activity of cytochrome P450(C17) from the testis of Bufo arenarum. J Comp Physiol B. 2002;172(8):685-90.
366. Sheean GL, et al. An open-labelled clinical and electrophysiological study of 3, 4 diaminopyridine in the treatment of fatigue in multiple sclerosis. Brain. 1998;121(Pt 5):967-75.
367. Rossini PM, et al. Fatigue in progressive multiple sclerosis: results of a randomized, doubleblind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001;7(6):354-8.
368. Flet L, et al. 3, 4-diaminopyridine safety in clinical practice: an observational, retrospective cohort study. J Neurol. 2010;257(6):937-46.
369. Tejani AM, et al. Carnitine for fatigue in multiple sclerosis. Cochrane Database Syst Rev. 2010;(2):CD007280.
370. Tomassini V, et al. Comparison of the effects of acetyl L-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial. J Neurol Sci. 2004;218(1-2):103-8.
371. Kim E, et al. American ginseng does not improve fatigue in multiple sclerosis: a single center randomized double-blind placebo-controlled crossover pilot study. Mult Scler. 2011;17(12): 1523-6.
372. Caminero A, Bartolome M. Sleep disturbances in multiple sclerosis. J Neurol Sci. 2011;309(1-2):86-91.
373. Brass SD, et al. Sleep disorders in patients with multiple sclerosis. Sleep Med Rev. 2010;14(2):121-9.
374. Newman NJ. Multiple sclerosis and related demyelinating diseases. In: Miller NR, Newman NJ, editors. Walsh and Hoyt's clinical neuro-ophthalmology. Baltimore: Williams and Wilkins; 1998. p. 5539-76.
375. Ganley JP. Uveitis and multiple sclerosis: an overview. In: Saari KM, editor. Uveitis update. Amsterdam: Excerpta Medica; 1984. p. 345-9.
376. Rushton D, Cox N. A new optical treatment for oscillopsia. J Neurol Neurosurg Psychiatry. 1987;50(4):411-5.
377. Starck M, et al. Acquired pendular nystagmus in multiple sclerosis: an examiner-blind crossover treatment study of memantine and gabapentin. J Neurol. 2010;257(3):322-7.
378. Leigh RJ, et al. Crossover trial of gabapentin and memantine as treatment for acquired nystagmus. Ann Neurol. 2010;67(5):676-80.
379. Strupp M, et al. Treatment of downbeat nystagmus with 3, 4-diaminopyridine: a placebocontrolled study. Neurology. 2003;61(2):165-70.
380. Kalla R, et al. 4-aminopyridine improves downbeat nystagmus, smooth pursuit, and VOR gain. Neurology. 2004;62(7):1228-9.
381. Kalla R, et al. Comparison of 10-mg Doses of 4-Aminopyridine and 3, 4-Diaminopyridine for the Treatment of Downbeat Nystagmus. J Neuroophthalmol. 2011;31(4):320-5.
382. Averbuch-Heller L. Acquired nystagmus. Curr Treat Options Neurol. 1999;1(1):68-73.
383. Menon GJ, Thaller VT. Therapeutic external ophthalmoplegia with bilateral retrobulbar botulinum toxin- an effective treatment for acquired nystagmus with oscillopsia. Eye (Lond). 2002;16(6):804-6.
384. Ruben ST, et al. The use of botulinum toxin for treatment of acquired nystagmus and oscillopsia. Ophthalmology. 1994;101(4):783-7.
385. Adams WE, Leavitt JA, Holmes JM. Strabismus surgery for internuclear ophthalmoplegia with exotropia in multiple sclerosis. J AAPOS. 2009;13(1):13-5.
386. Thomas FJ, Wiles CM. Dysphagia and nutritional status in multiple sclerosis. J Neurol. 1999;246(8):677-82.
387. Giusti A, Giambuzzi M. Management of dysphagia in patients affected by multiple sclerosis: state of the art. Neurol Sci. 2008;29 Suppl 4:S364-6.
388. Alfonsi E, et al. An electrophysiological approach to the diagnosis of neurogenic dysphagia: implications for botulinum toxin treatment. J Neurol Neurosurg Psychiatry. 2010;81(1): 54-60.
389. Restivo DA, et al. Botulinum toxin improves dysphagia associated with multiple sclerosis. Eur J Neurol. 2011;18(3):486-90.
390. Marrosu F, et al. Vagal nerve stimulation improves cerebellar tremor and dysphagia in multiple sclerosis. Mult Scler. 2007;13(9):1200-2.
391. Beukelman DR, Kraft GH, Freal J. Expressive communication disorders in persons with multiple sclerosis: a survey. Arch Phys Med Rehabil. 1985;66(10):675-7.
392. Hartelius L, Svensson P. Speech and swallowing symptoms associated with Parkinson's disease and multiple sclerosis: a survey. Folia Phoniatr Logop. 1994;46(1):9-17.
393. Hartelius L, Runmarker B, Andersen O. Prevalence and characteristics of dysarthria in a multiple-sclerosis incidence cohort: relation to neurological data. Folia Phoniatr Logop. 2000;52(4):160-77.
394. Darley FL, Brown JR, Goldstein NP. Dysarthria in multiple sclerosis. J Speech Hear Res. 1972;15(2):229-45.
395. Parker M, et al. Automatic speech recognition and training for severely dysarthric users of assistive technology: the STARDUST project. Clin Linguist Phon. 2006;20(2-3):149-56.
396. Blanco Y, et al. Midbrain lesions and paroxysmal dysarthria in multiple sclerosis. Mult Scler. 2008;14(5):694-7.
397. Valentino P, et al. Lamotrigine therapy for paroxysmal dysarthria caused by multiple sclerosis: a case report. J Neurol. 2011;258(7):1349-50.
398. Voiculescu V, Pruskauer-Apostol B, Alecu C. Treatment with acetazolamide of brain-stem and spinal paroxysmal disturbances in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1975;38(2):191-3.
399. Lensch E, Jost WH. Autonomic disorders in multiple sclerosis. Autoimmune Dis. 2011;2011:803841.
400. Davis SL, et al. Thermoregulation in multiple sclerosis. J Appl Physiol. 2010;109(5): 1531-7.
401. Higginson IJ, et al. Symptom prevalence and severity in people severely affected by multiple sclerosis. J Palliat Care. 2006;22(3):158-65.
402. O'Brien T. Neurodegenerative disease. In: Addington-Hall JM, Higginson IJ, editors. Palliative care for non-cancer patients. Oxford: Oxford University Press; 2001. p. 44-55.
403. Kumpfel T, et al. Palliative care in patients with severe multiple sclerosis: two case reports and a survey among German MS neurologists. Palliat Med. 2007;21(2):109-14.
404. Higginson IJ, et al. Is short-term palliative care cost-effective in multiple sclerosis? A randomized phase II trial. J Pain Symptom Manage. 2009;38(6):816-26.
405. Edmonds P, et al. Palliative care for people severely affected by multiple sclerosis: evaluation of a novel palliative care service. Mult Scler. 2010;16(5):627-36.
406. Golla H, et al. Unmet needs of severely affected multiple sclerosis patients: the health professionals' view. Palliat Med. 2012;26(2):139-51.
407. Department of Health Long-term Conditions NSF Team. The National Service Framework for Long-term Conditions. London: DH; 2005. Department of Health, UK Government.
408. Guideline Development Group. Longterm neurological conditions: management at the interface between neurology, rehabilitation and palliative care. London: Royal College of Physicians; 2008.
409. Campbell CW, Jones EJ, Merrills J. Palliative and end-of-life care in advanced Parkinson's disease and multiple sclerosis. Clin Med. 2010;10(3):290-2.